CanStem111P trial: A Phase III study of napabucasin plus nab-paclitaxel with gemcitabine

Mohamad Bassam Sonbol, Daniel H. Ahn, David Goldstein, Takuji Okusaka, Josep Tabernero, Teresa Macarulla, Michele Reni, Chung Pin Li, Bert O'Neil, Eric Van Cutsem, Tanios Bekaii-Saab

Research output: Contribution to journalArticleResearch

19 Citations (Scopus)


© 2019 Future Medicine Ltd. Napabucasin (also known as BBI-608 or BBI608) is an investigational, oral agent hypothesized to inhibit multiple oncogenic pathways. In this article, we describe the design and rationale for the CanStem111P clinical trial, a multicenter, randomized, open-label, Phase III study designed to determine the efficacy and safety of combining napabucasin with nab-paclitaxel and gemcitabine for first-line treatment of patients with metastatic pancreatic adenocarcinoma (NCT02993731). Patients were randomized in a 1:1 fashion to receive weekly gemcitabine and nab-paclitaxel with or without napabucasin. The results of this study will help define the role of this novel agent in the management of advanced pancreatic cancer.
Original languageEnglish
Pages (from-to)1295-1302
JournalFuture Oncology
Publication statusPublished - 1 Apr 2019


  • BBI-608
  • cancer stem cells
  • CanStem111P
  • napabucasin
  • pancreatic adenocarcinoma


Dive into the research topics of 'CanStem111P trial: A Phase III study of napabucasin plus nab-paclitaxel with gemcitabine'. Together they form a unique fingerprint.

Cite this